D
Dan Nordström
Researcher at University of Helsinki
Publications - 194
Citations - 4575
Dan Nordström is an academic researcher from University of Helsinki. The author has contributed to research in topics: Rheumatoid arthritis & Internal medicine. The author has an hindex of 33, co-authored 168 publications receiving 3944 citations. Previous affiliations of Dan Nordström include Helsinki University Central Hospital.
Papers
More filters
Journal ArticleDOI
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis
Paul Emery,Ferdinand C. Breedveld,E M Lemmel,J P Kaltwasser,P T Dawes,B Gömör,F Van Den Bosch,Dan Nordström,O Bjorneboe,R Dahl,Kim Hørslev-Petersen,A Rodriguez De La Serna,Michael G. Molloy,Mohammed Tikly,C. Oed,Ronald Rosenburg,I Loew-Friedrich +16 more
TL;DR: Both leflunomide and methotrexate are efficacious for prolonged treatment of RA and this benefit must be weighed against the potential toxicity of this drug when used without folate supplementation.
Journal ArticleDOI
Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis
TL;DR: No single substance clearly rose above others in efficacy, but the results of the safety analyses suggest that etanercept might be the safest alternative.
Journal ArticleDOI
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
Katerina Chatzidionysiou,Elisabeth Lie,Evgeny Nasonov,Galina Lukina,Merete Lund Hetland,Ulrik Tarp,Cem Gabay,Piet L. C. M. van Riel,Dan Nordström,Juan J. Gomez-Reino,Karel Pavelka,Matija Tomšič,Tore K Kvien,Ronald F van Vollenhoven +13 more
TL;DR: Effectiveness was best when RTX was used as the first biological agent or after failure of no more than one anti-tumour necrosis factor agent and seropositive patients achieved significantly greater reductions in DAS28 at 6 months than seronegative patients.
Journal ArticleDOI
Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still's Disease. An Open, Randomized, Multicenter Study
Dan Nordström,Ann Knight,Reijo Luukkainen,Ronald F van Vollenhoven,Vappu Rantalaiho,Anna Kajalainen,Johan G. Brun,Anne Prøven,Lotta Ljung,Hannu Kautiainen,Tom Pettersson +10 more
TL;DR: Anakinra induced more beneficial responses than DMARD in patients with AOSD and was favored in the open-label extension phase and wasavored in the OLE phase.
Journal ArticleDOI
Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations.
Christina Kaiser,Ann Knight,Dan Nordström,Tom Pettersson,Jonas Fransson,Ebba Florin-Robertsson,Björn Pilström +6 more
TL;DR: The present review summarises published data concerning ISRs associated with Kineret and provides some explanations as to their cause.